Quick Takeaways
- Avoro Capital Advisors LLC filed SCHEDULE 13G/A for Amicus Therapeutics, Inc. Common Stock, par value $0.01 per share (FOLD).
- Disclosed ownership: 6.7%.
- Date of event: 31 Mar 2025.
Avoro Capital Advisors LLC - 31 Mar 2025 SCHEDULE 13G/A Report for Amicus Therapeutics, Inc. Common Stock, par value $0.01 per share (FOLD)
- Filing Manager
- Avoro Capital Advisors LLC
- Reporting Manager
- Avoro Capital Advisors LLC
- Symbol
- FOLD
- Shares outstanding
- 305,970,149 shares
- Disclosed Ownership
- 20,500,000 shares
- Ownership
- 6.7%
- Form type
- SCHEDULE 13G/A
- Filing time
- 15 May 2025, 09:30:38 UTC
- Date of event
- 31 Mar 2025
- Next filing
- 14 Nov 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Avoro Capital Advisors LLC disclosed 6.7% ownership in Amicus Therapeutics, Inc. Common Stock, par value $0.01 per share (FOLD) on 31 Mar 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 15 May 2025, 09:30.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Avoro Capital Advisors LLC | 6.7% | 20,500,000 | 20,500,000 | 0 | /s/ Scott Epstein | Scott Epstein, Chief Financial Officer & Chief Compliance Officer | |
| Behzad Aghazadeh | 6.7% | 20,500,000 | 20,500,000 | 0 | /s/ Behzad Aghazadeh | Behzad Aghazadeh, Individually |